Innovation

In the 2021/2022 business year, we spent more than EUR 45 million on research and development

Egis Inaugurates Two New Plants in Körmend

Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October. In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products. Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing. More

Egis expands its portfolio with active pharmaceutical ingredient contract development and contract manufacturing

Egis Pharmaceuticals PLC, celebrating the 110th anniversary of its foundation this year, is expanding its usual activities with new elements thanks to investments exceeding a total value of more than HUF 100 billion in Hungary over the past decade. Egis, one of the leading generic pharmaceutical companies in Eastern and Central Europe, now offers drug substance contract development and contract manufacturing services under the name of Egis Pharma Services to both existing and new pharmaceutical partners. More

Study on Neuroscience Research wins Egis’ Prize this Year

As research and development are fundamental pillars of our strategy Egis is deeply committed to raise students’ interest in science and help the promising young minds develop their talents. That is why we have been supporting the annual ’Scientific and Innovation Talent Recruitment Contest for Youth’ for decades. This year, Egis’ prize went to undergraduate student Hunor Sebők. More

Strategic cooperation agreement between Semmelweis University and Egis

The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.

More

Egis Has Been Awarded for being a ’Future Proof Organization’

Microsoft and HR Fest — the largest HR professional festival in Hungary — established a new professional award category within HR Best awards called ‘Future Proof Organizations’.

More

New Unit Inaugurated at Egis’s Körmend Plant

Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realisation of the above-mentioned project.

More

Environment Protection - Electric Cars in the Egis Fleet

It is important for us to protect the future of our planet, therefore we try to reduce our ecological footprint. Egis uses more and more electric cars in its fleet in order to minimize the harmful substance output.

More

1
2

Other channels

Egis is present in 62 countries with its products.

Our mission is to serve people with all of our skills, ensuring that they live a long and healthy life

In the 2021/2022 business year, the company’s product portfolio consisted of 642 products

Corporate Social Responsibility

Healthcare and sharing knowledge are in the heart of our CSR activities

Our highlighted past and future events you shouldn't miss

Warning

Your browser is out of date. Please, use an updated version! Chrome || Firefox